Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aceso Life Science Group's EBIT per Share for the
six
months ended in Sep. 2025 was HK$0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was HK$-0.04.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Aceso Life Science Group's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Aceso Life Science Group was 61.30% per year. The lowest was -55.20% per year. And the median was 1.90% per year.
HKSE:00474's 3-Year EBIT Growth Rate is not ranked *
in the Business Services industry.
Industry Median: 8 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Aceso Life Science Group (HKSE:00474) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Aceso Life Science Group EBIT per Share Related Terms
Aceso Life Science Group EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aceso Life Science Group (HKSE:00474) has a EBIT per Share of HK$-0.04 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aceso Life Science Group and its competitors. According to the industry distribution chart, Aceso Life Science Group ranks #999999 out of 840 companies in the Business Services industry.
Is Aceso Life Science Group's EBIT per Share too high?
Aceso Life Science Group's current EBIT per Share is HK$-0.04. Based on the distribution chart, Aceso Life Science Group ranks #999999 out of 840 companies in the Business Services industry, which is in the bottom quartile relative to peers. Overall, Aceso Life Science Group has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aceso Life Science Group's EBIT per Share compare to URI and SUNB?
According to the Business Services industry distribution chart, Aceso Life Science Group ranks #999999 out of 840 companies for EBIT per Share. This places Aceso Life Science Group in the lower half of its industry. The industry median EBIT per Share is 8.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Business Services company?
The median EBIT per Share among Business Services companies is 8.00, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aceso Life Science Group and its competitors. For the Business Services industry, the median EBIT per Share is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aceso Life Science Group's current EBIT per Share is HK$-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aceso Life Science Group stock overvalued right now?
Based on GuruFocus' analysis, Aceso Life Science Group (HKSE:00474) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.08, compared to a current price of HK$0.15 — trading 87.5% above its estimated fair value. The current EBIT per Share is HK$-0.04. Aceso Life Science Group's overall GF Score™ is 19/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Aceso Life Science Group (HKSE:00474), the current EBIT per Share is HK$-0.04 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aceso Life Science Group (HKSE:00474) Overvalued in 2026?
Based on GuruFocus' analysis, Aceso Life Science Group stock appears to be overvalued.
The current stock price of HK$0.15 is trading 87.5% above its estimated GF Value™ of HK$0.08.
GuruFocus considers Aceso Life Science Group to be Significantly Overvalued.
Key valuation signals for HKSE:00474:
EBIT per Share: HK$-0.04
GF Value™: HK$0.08 vs. price of HK$0.15 (87.5% above fair value)
No single metric tells the full story. See the HKSE:00474 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aceso Life Science Group Ltd is an investment holding company. The group's operating segments include Money lending, Rental and sale of construction machinery and spare parts business, Provision of repair and maintenance and transportation service business, Provision of asset management, securities brokerage, commodities, futures, and other financial service business, Property leasing business, and Property development business. It derives key revenue from the rental and sale of construction machinery and spare parts. Geographically, the group has a business presence in Hong Kong, the UK, the PRC, Macau, and Cambodia.
19GF Score
Get the complete analysis for HKSE:00474
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00474 has been successfully added to your 
